


CLAIMS

1. A sulfonamide compound of general formula (Ia),



(Ia),

wherein

R¹ represents a -NR⁸R⁹ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R⁴ is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^8 and R^9 , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

5 with the proviso that R^8 and R^9 are not hydrogen at the same time, and if one of them, R^8 or R^9 , is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1 - C_4 aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms, or

10 R^8 and R^9 together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

20 and


25 n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

30

2. A compound according to claim 1, characterized in that R^1 represents a - NR^8R^9 radical or a saturated or unsaturated optionally at least mono-substituted 5- or 6-membered cycloaliphatic radical, which may optionally
 5 contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- or 6-membered,

10 preferably R^1 represents a - NR^8R^9 radical or a radical chosen from the group consisting of



15 wherein, if present, the dotted line represents an optional chemical bond, and R^{10} represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1 - C_2 alkyl radical.

3. A compound according to claim 1 or 2, characterized in that R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or
 20 branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

preferably R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

5

more preferably R^2 , R^3 , R^5 , R^6 and R^7 each represent hydrogen.

4. A compound according to one or more of claims 1 to 3, characterized in that R^4 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical

10

preferably R^4 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

15

more preferably R^4 represents hydrogen or a C_1 - C_2 alkyl radical.

5. A compound according to one or more of claims 1 to 4, characterized in that R^8 and R^9 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical, or

20

25

R^8 and R^9 together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered heterocyclic ring which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- 6- or 7-


30

membered.

6. A compound according to claim 5, characterized in that R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched C_1 - C_{10} alkyl radical,

or

R^8 and R^9 together with the bridging nitrogen atom form a radical chosen from the group consisting of




wherein R^{11} , if present, represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen, or a C_1 - C_2 alkyl radical.

7. A compound according to one or more of claims 1 to 6, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

5

or a radical chosen from the group consisting of



10 wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

15

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

20


W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R^{14} is hydrogen or a linear or branched C_1 - C_6 alkyl,

m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

8. A sulfonamide compound of general formula (Ib),



wherein

R^1 represents a $-NR^8R^9$ radical,

R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R^4 is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R^8 and R^9 , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_{1-4} aliphatic radical,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.


9. A compound according to claim 8, characterized in that R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

preferably R^2 , R^3 , R^5 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

more preferably R^2 , R^3 , R^5 , R^6 and R^7 each represent hydrogen.

10. A compound according to claim 8 or 9, characterized in that R^4 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1-C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2-C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2-C_6 alkynyl radical,
- preferably that R^4 represents hydrogen or a linear or branched, optionally at least substituted C_1-C_6 alkyl radical,
- more preferably R^4 represents hydrogen or a C_1-C_2 alkyl radical.
11. A compound according to one or more of claims 8 to 10, characterized in that R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1-C_4 alkyl radical,
- preferably R^8 and R^9 represent hydrogen or a C_1-C_2 alkyl radical, with the proviso that R^8 and R^9 are not hydrogen at the same time.
12. A compound according to one or more of claims 8 to 11, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1-C_6 alkylene group, an optionally at least mono-substituted C_2-C_6 alkenylene group or an optionally at least mono-substituted C_2-C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,
- preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

or a radical chosen from the group consisting of



5 wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

10

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

15

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

20


m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

13. A compound according to one or more of claims 8 to 12 selected from
5 the group consisting of
- [1] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- 10 [2] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphtalene-2-sulfonamide,
- [3] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphtalene-1-sulfonamide,
- 15 [4] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenylbenzenesulfonamide,
- [5] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-2-(naphtalene-1-yl)-ethanesulfonamide,
- 20 [6] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenoxybenzenesulfonamide,
- [7] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-3,5-dichlorobenzenesulfonamide and
- 25 [8] 6-chloro-N-[1-(2-dimethylaminoethyl)-1H-indol-4-yl]-imidazo[2,1-b]thiazole-5-sulfonamide
- 30


and their corresponding salts and solvates.

14. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, characterized in that a compound of general formula (II), or one of its suitably protected derivatives,



(II)

wherein A has the meaning according to one or more of claims 1 - 13, and X is an acceptable leaving group, preferably a halogen atom, more preferably chlorine is reacted with at least one 4-aminoindole of general formula (III), or one of its suitably protected derivatives;



(III)

wherein R^1 - R^7 and n have the meaning according to one or more of claims 1 - 13 to obtain the corresponding sulfonamide and optionally, from the latter, the protective groups may be removed if necessary.

15. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, wherein R^1 - R^3 , R^5 - R^7 , n and A have the meaning according to one or more of claims 1 - 13, and R^4 represents C_1 - C_6 alkyl, characterized by reacting at least one compound of general formula (Ia) and/or at least one compound of general formula (Ib), wherein R^1 - R^3 , R^5 - R^7 , n and A have the meaning according to one or more of claims 1 - 13, and R^4 represents an hydrogen atom, with an alkyl halogenide or dialkyl sulfate.

16. A process for preparing the salts, preferably the physiologically acceptable salts of the compounds of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, consisting of reacting at least one compound of the general formula (Ia) and/or at least one compound of the general formula (Ib) with a mineral acid or organic acid in a suitable solvent.
17. A medicament comprising least one compound according to one or more of claims 1 to 7 and optionally one or more pharmacologically acceptable excipients.
18. A medicament according to claim 17, for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),
- preferably for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia,

anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.

5

19. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for 5-HT₆ receptor regulation.

10

20. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.

15

21. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the regulation of appetite.

22. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.

20

23. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

25

24. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.

30

25. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.

26. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 5 27. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 10 28. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 15 29. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 20 30. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 25 31. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
32. The use of at least one compound according to one more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
- 30 33. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.

34. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 5 35. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 10 36. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 15 37. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 20 38. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 25 39. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 30 40. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.

41. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 5 42. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 10 43. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 15 44. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for cognitive enhancement.
45. A medicament comprising at least one compound according to one or more of claims 8 to 13 and optionally one or more pharmacologically acceptable excipients.
- 20 46. A medicament according to claim 45 for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease,
- 25 30

Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),

- 5 preferably for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and
- 10 multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
47. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for 5-HT₆ receptor regulation.
- 15 48. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.
- 20 49. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the regulation of appetite.
50. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the maintenance, increase
- 25 or reduction of body weight.
51. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

52. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 5 53. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.
- 10 54. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 15 55. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 20 56. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 25 57. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
58. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 30 59. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.

- 5
60. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
61. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 10 62. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 15 63. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 20 64. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 25 65. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 30 66. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
67. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.

- 5 68. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.
69. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 10 70. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 15 71. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 20 72. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for cognitive enhancement.